U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07293403) titled 'Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas' on Dec. 15.
Brief Summary: This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.
Study Start Date: June 07, 2026
Study Type: INTERVENTIONAL
Condition:
Follicular Helper T-Cell Lymphoma
Peripheral T-Cell Ly...